BioCentury
ARTICLE | Clinical News

IVA337: Phase IIb started

February 8, 2016 8:00 AM UTC

Inventiva began the double-blind, placebo-controlled, international Phase IIb FASST trial to evaluate 800 and 1,200 mg oral IVA337 daily for 48 weeks in about 105 patients. ...